<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651105</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2347</org_study_id>
    <nct_id>NCT00651105</nct_id>
  </id_info>
  <brief_title>Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Cross-over Study to Evaluate the GLP-1-mediated and Non-GLP-1-mediated Effects of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the GLP-1 and non-GLP-1 effects of LAF237 on glucagon
      secretion, using treatment observations of the overall glycemic response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GLP-1 and non GLP-1 effects of LAF237 on glucagon secretion in patients with Type-2 diabetes and matching healthy subjects</measure>
    <time_frame>from baseline to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of LAF237 on prandial glucose profiles, prandial insulin, and gastric-emptying in patients with Type-2 diabetes and in matching healthy subjects.</measure>
    <time_frame>10 day treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Type-2 Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria - Type-2 Diabetes Patients

          -  Male or female patients aged 30 to 75 years with Type-2 Diabetes Mellitus (T2DM) and
             who are in otherwise good health

          -  Must have been diagnosed with T2DM at least 6 months prior to screening, and whose
             diabetes is controlled by diet and exercise alone or by stable dosage ( &gt; 3 months) of
             metformin

          -  HbA1c in the range of 6.5% to 9% at screening

        Inclusion Criteria - Healthy Volunteers

          -  Male or female subjects aged 30 to 75 years, determined to be in good health

          -  Normal oral glucose tolerance test (OGTT) at screening

          -  Age, gender and weight matched to subjects with T2DM

        Exclusion Criteria:

        Exclusion criteria - Type-2 Diabetes Patients

          -  A history of:

          -  Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of
             diabetes, e.g., Cushing's syndrome and acromegaly

          -  Acute metabolic diabetic complications (such as ketoacidosis or hyperosmolar state
             (coma)) within the past 6 months

          -  Torsades de Pointes, ventricular tachycardia or ventricular fibrillation

          -  Any severe hypoglycemic episode within 3 months of screening

          -  Use of any of the following medications:

          -  Antihypertensive or lipid-lowering agents unless on a stable dose for at least 3
             months prior to screening

          -  Chronic insulin treatment (&gt; 4 weeks of treatment in the absence of an intercurrent
             illness) within the past 6 months

          -  Chronic oral/intramuscular/intravenous corticosteroid treatment ( &gt; 7 consecutive days
             of treatment) within 8 weeks prior to screening

        Exclusion Criteria - Healthy Volunteers

          -  First degree relative of an individual with T2DM

          -  History of gestational diabetes

          -  Use of any prescription medication within 1 month prior to dosing. Use of
             over-the-counter medications or vitamins within 14 days prior to dosing.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Bad Lauterberg im Harz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3044</url>
    <description>Results for CLAF237A2347 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Nauck MA, Kind J, KÃ¶the LD, Holst JJ, Deacon CF, Broschag M, He YL, Kjems L, Foley J. Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. Diabetes. 2016 Aug;65(8):2440-7. doi: 10.2337/db16-0107. Epub 2016 Apr 5.</citation>
    <PMID>27207543</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Healthy</keyword>
  <keyword>Vildagliptin</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

